A 2022 investigation using a PheWAS approach in an earlier version of UKBB reported an excess risk (OR>3) for leukemia and plasma cell neoplasms in CHEK2 P/LP heterozygotes.28 To date with current approaches (e.g., CBC, physical exam) there is limited evidence-based actionability for surveillance for increased risk of leukemia, however with developing methods (e.g., methylation profiling of circulating tumor DNA) this may improve. The gene discussed is CHEK2; the disease is leukemia.